Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Hu5F9-G4 + Sacituzumab govitecan-hziy|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Hu5F9-G4||Magrolimab|Hu5F9 G4|GS-4721||CD47 Antibody 20 Immune Checkpoint Inhibitor 146||Magrolimab (Hu5F9-G4) is a humanized monoclonal antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells (PMID: 26390038, PMID: 28286286) and may also stimulate cytotoxic T-cells (PMID: 29873856).|
|Sacituzumab govitecan-hziy||Trodelvy||IMMU-132|Sactizumab||Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate composed of a monoclonal anti-TROP2 antibody linked to the active metabolite of irinotecan (SN-38), which binds to TROP2 positive cancer cells and induces DNA breakage and apoptosis (PMID: 26541586). Trodelvy (sacituzumab govitecan-hziy) is FDA approved for use in patients with metastatic triple-negative breast cancer who received two or more prior therapies, and in patients with locally advanced or metastatic urothelial cancer who received a platinum-containing chemotherapy and a PD-1 orPD-L1 inhibitor (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04958785||Phase II||Hu5F9-G4 + Nab-paclitaxel Hu5F9-G4 + Sacituzumab govitecan-hziy Nab-paclitaxel Paclitaxel Hu5F9-G4 + Paclitaxel||Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Adults With Metastatic Triple-Negative Breast Cancer||Recruiting||USA||2|